KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EPS (Basic): 2009-2024

Historic EPS (Basic) for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Dec 2024 value amounting to $2.25.

  • Biomarin Pharmaceutical's EPS (Basic) fell 128.57% to -$0.16 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.72, marking a year-over-year increase of 60.00%. This contributed to the annual value of $2.25 for FY2024, which is 152.81% up from last year.
  • Latest data reveals that Biomarin Pharmaceutical reported EPS (Basic) of $2.25 as of FY2024, which was up 152.81% from $0.89 recorded in FY2023.
  • In the past 5 years, Biomarin Pharmaceutical's EPS (Basic) registered a high of $4.72 during FY2020, and its lowest value of -$0.35 during FY2021.
  • In the last 3 years, Biomarin Pharmaceutical's EPS (Basic) had a median value of $0.89 in 2023 and averaged $1.30.
  • In the last 5 years, Biomarin Pharmaceutical's EPS (Basic) surged by 3,730.77% in 2020 and then crashed by 107.42% in 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's EPS (Basic) (Yearly) stood at $4.72 in 2020, then plummeted by 107.42% to -$0.35 in 2021, then skyrocketed by 317.14% to $0.76 in 2022, then rose by 17.11% to $0.89 in 2023, then spiked by 152.81% to $2.25 in 2024.